Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ansell SM et al. – Blockade of CTLA–4 signaling with the use of ipilimumab is well tolerated at the doses used and has antitumor activity in patients with B–cell lymphoma. Further evaluation of ipilimumab alone or in combination with other agents in B–cell lymphoma patients is therefore warranted.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address